Tsujimoto T, et al. - Researchers investigated if the plasminogen activator inhibitor-1/tissue plasminogen activator (PAI-1/tPA) ratio as a prothrombotic state has utility for optimizing cardiac treatment strategy by analyzing BARI 2D trial data for patients receiving early revascularization (percutaneous coronary intervention (PCI) or coronary artery bypass grafting) or medical therapy. They calculated HRs with 95% CIs for cardiac events in these patients, separately in patients with low (n=1,276) and high (n=894) PAI-1/tPA ratios. They utilized a Cox proportional hazard model and participants were followed-up for a mean±SD duration of 4.1±1.7 years. Findings revealed higher risks of major cardiac events in patients with type 2 diabetes mellitus and coronary artery disease when treated with PCI vs intensive medical therapy.